The first experience of application of the drug «Coronaket» containing GS-441524 against feline infectious peritonitis

Feline infectious peritonitis until recently, due to the lack of etiotropic therapy, was considered an incurable disease with a 99% fatal outcome. One most effective agents nucleoside analogue GS-441524, developed by Gilead Sciences. Until preparations containing GS-441524 were typically manufactured in China and not licensed. «Coronacat» is first registered drug certificate GMP facility Europe for treatment feline (developer VETUCHASTOK LLC, manufacturer ‒ Promvetservice-Alba branch Promvetservis LLC). The article describes results evaluating efficacy safety viral peritonitis. 1 ml preparation contains 10 mg GS-441524. object study 20 cats aged 6 months 5 years Cats divided into 2 groups: animals experimental group (using test drug) historical control (without use drug, based on archival data). effectiveness assessed according following criteria: 1) survival (life expectancy when studying methods); 2) presence adverse reactions drugs; 3) - change parameters blood electrophoresis. data obtained indicate that contrast standard regimen, showed high efficiency course 84 injections (1 time per day), if necessary, can be extended. decision need extend should made animal's attending physician.